Skip Navigation

European Heart Journal 1995 16(3):377-382;
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by REISINGER, J.
Right arrow Articles by BORGGREFE, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by REISINGER, J.
Right arrow Articles by BORGGREFE, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy

J. REISINGER, M. SHENASA, A. LUBINSKI, G. HINDRICKS, W. HAVERKAMP, X. CHEN, G. BREITHARDT and M. BORGGREFE

The Hospital of the Westfälische Wilhelms-Universität Münster, Department of Cardiology and Angiology Münster, Germany

accepted 28 August 1994.

Correspondence: Marun Borggrefe, MD Medizinische Klinik und Poliklinik, University Hospital of Munster, Westfälische Wilhelms Universität, Albert Schweitzer-Str. 33, D 48129 Münster, Germany.

Abstract

In 90 consecutive patients with coronary artery disease and sustained monomorphic ventricular tachycardia, who were treated with oral sotalol and underwent programmed stimulation to determine drug effectiveness, the influence of sotalol on induced ventricular tachycardia morphology was retrospectively examined. In 54 patients (60%) sotalol rendered the tachycardia non-inducible. However, contrary to drug-testing with class I antiarrhythmic agents, induction of multiple morphologies at baseline study did not predict failure of subsequent drug-testing with sotalol. In the remaining 36 patients (40%), in whom sotalol did not modify inducibility, 21 patients (i.e. a total of 23%) manifested at least one new morphology during electropharmacological testing on sotalol. This effect was independent of the degree of left ventricular dysfunction, infarct location and numbers of morphologies at baseline, but corresponded with drug-induced changes in refractoriness. This observation may be related to a proarrhythmic effect of sotalol. Slowing of ventricular tachycardia rate and changes in morphology may have implications in patients receiving implantable cardioverter-defibrillators or those undergoing ablative procedures.

Key Words: Pleomorphism • ventricular tachycardia • refractoriness • sotalol • drug testing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.